158 related articles for article (PubMed ID: 26646377)
1. Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy.
Zoja C; Locatelli M; Corna D; Villa S; Rottoli D; Nava V; Verde R; Piscitelli F; Di Marzo V; Fingerle J; Adam JM; Rothenhaeusler B; Ottaviani G; Bénardeau A; Abbate M; Remuzzi G; Benigni A
Nephron; 2016; 132(1):59-69. PubMed ID: 26646377
[TBL] [Abstract][Full Text] [Related]
2. Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice.
Barutta F; Grimaldi S; Franco I; Bellini S; Gambino R; Pinach S; Corbelli A; Bruno G; Rastaldi MP; Aveta T; Hirsch E; Di Marzo V; Gruden G
Kidney Int; 2014 Nov; 86(5):979-90. PubMed ID: 24827776
[TBL] [Abstract][Full Text] [Related]
3. Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy.
Barutta F; Piscitelli F; Pinach S; Bruno G; Gambino R; Rastaldi MP; Salvidio G; Di Marzo V; Cavallo Perin P; Gruden G
Diabetes; 2011 Sep; 60(9):2386-96. PubMed ID: 21810593
[TBL] [Abstract][Full Text] [Related]
4. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
[TBL] [Abstract][Full Text] [Related]
5. Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A/caveolin-1/PV-1 signaling pathway.
Locatelli M; Zoja C; Conti S; Cerullo D; Corna D; Rottoli D; Zanchi C; Tomasoni S; Remuzzi G; Benigni A
J Pathol; 2022 Apr; 256(4):468-479. PubMed ID: 35000230
[TBL] [Abstract][Full Text] [Related]
6. Effects of CP-900691, a novel peroxisome proliferator-activated receptor α, agonist on diabetic nephropathy in the BTBR ob/ob mouse.
Askari B; Wietecha T; Hudkins KL; Fox EJ; O'Brien KD; Kim J; Nguyen TQ; Alpers CE
Lab Invest; 2014 Aug; 94(8):851-62. PubMed ID: 24955894
[TBL] [Abstract][Full Text] [Related]
7. Lithium reduces blood glucose levels, but aggravates albuminuria in BTBR-ob/ob mice.
de Groot T; Damen L; Kosse L; Alsady M; Doty R; Baumgarten R; Sheehan S; van der Vlag J; Korstanje R; Deen PMT
PLoS One; 2017; 12(12):e0189485. PubMed ID: 29244860
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological PAR-1 inhibition reduces blood glucose levels but does not improve kidney function in experimental type 2 diabetic nephropathy.
Waasdorp M; Florquin S; Duitman J; Spek CA
FASEB J; 2019 Oct; 33(10):10966-10972. PubMed ID: 31287960
[TBL] [Abstract][Full Text] [Related]
9. Probucol inhibited Nox2 expression and attenuated podocyte injury in type 2 diabetic nephropathy of db/db mice.
Zhou G; Wang Y; He P; Li D
Biol Pharm Bull; 2013; 36(12):1883-90. PubMed ID: 24432375
[TBL] [Abstract][Full Text] [Related]
10. Amelioration of renal alterations in obese type 2 diabetic mice by vasohibin-1, a negative feedback regulator of angiogenesis.
Saito D; Maeshima Y; Nasu T; Yamasaki H; Tanabe K; Sugiyama H; Sonoda H; Sato Y; Makino H
Am J Physiol Renal Physiol; 2011 Apr; 300(4):F873-86. PubMed ID: 21228103
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid receptors in the kidney.
Hryciw DH; McAinch AJ
Curr Opin Nephrol Hypertens; 2016 Sep; 25(5):459-64. PubMed ID: 27367912
[TBL] [Abstract][Full Text] [Related]
12. Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy.
Cassis P; Locatelli M; Corna D; Villa S; Rottoli D; Cerullo D; Abbate M; Remuzzi G; Benigni A; Zoja C
Kidney Int; 2019 Oct; 96(4):906-917. PubMed ID: 31307778
[TBL] [Abstract][Full Text] [Related]
13. Manipulating Sirtuin 3 pathway ameliorates renal damage in experimental diabetes.
Locatelli M; Zoja C; Zanchi C; Corna D; Villa S; Bolognini S; Novelli R; Perico L; Remuzzi G; Benigni A; Cassis P
Sci Rep; 2020 May; 10(1):8418. PubMed ID: 32439965
[TBL] [Abstract][Full Text] [Related]
14. Carnosine Attenuates the Development of both Type 2 Diabetes and Diabetic Nephropathy in BTBR ob/ob Mice.
Albrecht T; Schilperoort M; Zhang S; Braun JD; Qiu J; Rodriguez A; Pastene DO; Krämer BK; Köppel H; Baelde H; de Heer E; Anna Altomare A; Regazzoni L; Denisi A; Aldini G; van den Born J; Yard BA; Hauske SJ
Sci Rep; 2017 Mar; 7():44492. PubMed ID: 28281693
[TBL] [Abstract][Full Text] [Related]
15. The effects of dual PPAR
Ericsson A; Tonelius P; Lal M; Sabirsh A; Böttcher G; William-Olsson L; Strömstedt M; Johansson C; Hyberg G; Tapani S; Jönsson-Rylander AC; Unwin R
Physiol Rep; 2017 Mar; 5(5):. PubMed ID: 28292877
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor-δ activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes.
Lee EY; Kim GT; Hyun M; Kim S; Seok S; Choi R; Lee MY; Chung CH
Nephrol Dial Transplant; 2012 Nov; 27(11):4069-79. PubMed ID: 22892126
[TBL] [Abstract][Full Text] [Related]
17. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy.
Sanchez-Niño MD; Bozic M; Córdoba-Lanús E; Valcheva P; Gracia O; Ibarz M; Fernandez E; Navarro-Gonzalez JF; Ortiz A; Valdivielso JM
Am J Physiol Renal Physiol; 2012 Mar; 302(6):F647-57. PubMed ID: 22169009
[TBL] [Abstract][Full Text] [Related]
18. Lymphocytes promote albuminuria, but not renal dysfunction or histological damage in a mouse model of diabetic renal injury.
Lim AK; Ma FY; Nikolic-Paterson DJ; Kitching AR; Thomas MC; Tesch GH
Diabetologia; 2010 Aug; 53(8):1772-82. PubMed ID: 20422398
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid 2 Receptor Agonist Improves Systemic Sensitivity to Insulin in High-Fat Diet/Streptozotocin-Induced Diabetic Mice.
Zhang X; Gao S; Niu J; Li P; Deng J; Xu S; Wang Z; Wang W; Kong D; Li C
Cell Physiol Biochem; 2016; 40(5):1175-1185. PubMed ID: 27960161
[TBL] [Abstract][Full Text] [Related]
20. Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy.
Jourdan T; Szanda G; Rosenberg AZ; Tam J; Earley BJ; Godlewski G; Cinar R; Liu Z; Liu J; Ju C; Pacher P; Kunos G
Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5420-8. PubMed ID: 25422468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
